Test Hypotheses Against Linked Evidence

 BGPT Odds of True

The hypothesis proposes a specific mechanistic chain — impaired antigen presentation plus reduced granzyme clearance in gut tissue enabling defective viral genome persistence in PASC. No supplied evidence tests any link in this chain; it remains a mechanistic conjecture, rated low-moderate pending direct gut-tissue immune and viral persistence data.

 Hypothesis Novelty

Combining antigen-presentation downregulation, granzyme clearance impairment, gut tissue residence, and defective-genome culture-negative persistence into a single PASC mechanism is a relatively specific unexplored synthesis, though each component draws on known immunology of persistent viral infections.

 Long Analysis Plan Copied

Evidence Gap: Supplied Records Cannot Test This Hypothesis

The question of whether reduced antigen presentation and granzyme-mediated clearance in gut tissue permit culture-negative persistence of defective SARS-CoV-2 genomes in PASC requires direct studies of gut biopsies, immune effector function, and viral RNA persistence — none of which appear in the supplied evidence records.

The closest tangential findings are: (1) SARS-CoV-2 infection independently increased leukopenia risk in transplant recipients (IRR 7.1, 95% CI 2.8–18.1, p < 0.001), while mRNA vaccination did not alter leukocyte counts, suggesting infection but not vaccination perturbs immune cell populations in immunocompromised hosts Transplant leukocyte study; and (2) in children with HIV, impaired serological responses were suggested by lower seroprevalence at CD4 <350 cells/μL (46% vs 59%), a marker of altered antiviral immunity CALWHIV seroprevalence cohort.

What is missing: No supplied record measures MHC-I downregulation, granzyme B/perforin expression, cytotoxic T-cell function, or viral RNA quantification in gastrointestinal tissue of PASC patients. The hypothesis is plausible but entirely untested by available data; a rigorous verdict requires targeted single-cell RNA-seq/spatial profiling and strand-specific viral RNA assays from PASC gut biopsies versus controls.